Gedeon Richter Stock OTC Markets

Equities

GEDSF

US3684672054

Pharmaceuticals

Market Closed - OTC Markets 09:30:03 2024-04-03 EDT 5-day change 1st Jan Change
24.85 USD +4.85% Intraday chart for Gedeon Richter -.--% +4.85%

Financials

Sales 2024 * 837B 2.36B 3.23B Sales 2025 * 914B 2.58B 3.53B Capitalization 1,716B 4.84B 6.63B
Net income 2024 * 250B 706M 966M Net income 2025 * 269B 759M 1.04B EV / Sales 2024 * 1.9 x
Net cash position 2024 * 127B 359M 491M Net cash position 2025 * 195B 550M 753M EV / Sales 2025 * 1.66 x
P/E ratio 2024 *
7.12 x
P/E ratio 2025 *
6.49 x
Employees 11,603
Yield 2024 *
5.95%
Yield 2025 *
6.31%
Free-Float 73.04%
More Fundamentals * Assessed data
Dynamic Chart
Gedeon Richter Plc. Announces Directorate Changes CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Gedeon Richter Plc. Proposes Dividend CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Q4 2023 Earnings Call, Feb 29, 2024
Gedeon Richter plc announces Board Changes, Effective 1 March 2024 CI
Formycon Sells 9% Interest to Gedeon Richter for EUR83 Million MT
GRANATA BIO Corp announced that it has received $14 million in funding from GV Management Company, LLC, CooperSurgical, Inc., Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Alumni Ventures Group, LLC, Vibe Biotechnology Inc., Amboy Street Ventures and other investors. CI
Mithra Signs Agreement with Gedeon Richter for Commercialization of Estelle, Donesta in China MT
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Q3 2023 Earnings Call, Nov 08, 2023
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for  Commercialisation of RYEQO® CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis CI
GRANATA BIO Corp announced that it expects to receive $15.590561 million in funding from GV Management Company, LLC, CooperSurgical, Inc., Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt., Alumni Ventures Group, LLC, Vibe Biotechnology Inc., Amboy Street Ventures CI
More news
1 day+4.85%
3 months+4.85%
6 months+3.54%
Current year+4.85%
More quotes
Current year
24.85
Extreme 24.8501
24.85
1 year
23.55
Extreme 23.55
25.95
3 years
17.54
Extreme 17.54
28.37
5 years
17.54
Extreme 17.54
28.37
10 years
14.95
Extreme 14.951
28.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 45 -
Director of Finance/CFO 57 21-12-31
Chief Tech/Sci/R&D Officer 64 83-12-31
Members of the board TitleAgeSince
Chief Executive Officer 45 -
Director of Finance/CFO 57 21-12-31
Chairman 88 07-12-31
More insiders
Richter Gedeon Vegyeszeti Gyar Nyrt is a Hungary-based company engaged in the research, development, production and marketing and trade of pharmaceutical products. The Company’s business is structured into three segments: the Pharmaceuticals segment, which includes the companies that are involved in the Company’s core business, including research, development and production of pharmaceutical products; the Wholesale and retail segment covers distribution companies and pharmacies that are part of the sales network in various regional markets and, as such convey its products to consumers, and the Other segment presents all the other consolidated companies that provide marketing and sales support services. The Company’s subsidiaries include, among others, Gedeon Richter Romania SA, Gedeon Richter Polska Sp Z.o.o., and ZAO Gedeon Richter-RUS.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
9,390 HUF
Average target price
11,671 HUF
Spread / Average Target
+24.29%
Consensus

Quarterly revenue - Rate of surprise